260 related articles for article (PubMed ID: 23807861)
1. Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
Saif MW
Cancer Manag Res; 2013; 5():103-15. PubMed ID: 23807861
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
3. Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer.
Smaglo BG; Hwang J
J Gastrointest Oncol; 2013 Sep; 4(3):299-307. PubMed ID: 23997941
[TBL] [Abstract][Full Text] [Related]
4. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.
Chung C; Pherwani N
Am J Health Syst Pharm; 2013 Nov; 70(21):1887-96. PubMed ID: 24128964
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
Mitchell EP
Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
[TBL] [Abstract][Full Text] [Related]
6. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2014 Sep; 13(3):135-44. PubMed ID: 24768040
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
Lacal PM; Graziani G
Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy.
Sun W
J Hematol Oncol; 2012 Oct; 5():63. PubMed ID: 23057939
[TBL] [Abstract][Full Text] [Related]
9. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer.
Fakih M
Expert Rev Anticancer Ther; 2013 Apr; 13(4):427-38. PubMed ID: 23432698
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenesis agents in colorectal cancer.
Hubbard J; Grothey A
Curr Opin Oncol; 2010 Jul; 22(4):374-80. PubMed ID: 20375894
[TBL] [Abstract][Full Text] [Related]
11. Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer.
Chiron M; Bagley RG; Pollard J; Mankoo PK; Henry C; Vincent L; Geslin C; Baltes N; Bergstrom DA
Mol Cancer Ther; 2014 Jun; 13(6):1636-44. PubMed ID: 24688047
[TBL] [Abstract][Full Text] [Related]
12. Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept.
de Oliveira Dias JR; de Andrade GC; Novais EA; Farah ME; Rodrigues EB
Int J Retina Vitreous; 2016; 2():3. PubMed ID: 27847621
[TBL] [Abstract][Full Text] [Related]
13. The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC).
He K; Cui B; Li G; Wang H; Jin K; Teng L
Onco Targets Ther; 2012; 5():59-65. PubMed ID: 22570554
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenesis therapy in the treatment of metastatic colorectal cancer.
Grothey A; Allegra C
Ther Adv Med Oncol; 2012 Nov; 4(6):301-19. PubMed ID: 23118806
[TBL] [Abstract][Full Text] [Related]
15. Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data.
Muro K; Salinardi T; Singh AR; Macarulla T
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32244546
[TBL] [Abstract][Full Text] [Related]
16. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.
MacDonald DA; Martin J; Muthusamy KK; Luo JK; Pyles E; Rafique A; Huang T; Potocky T; Liu Y; Cao J; Bono F; Delesque N; Savi P; Francis J; Amirkhosravi A; Meyer T; Romano C; Glinka M; Yancopoulos GD; Stahl N; Wiegand SJ; Papadopoulos N
Angiogenesis; 2016 Jul; 19(3):389-406. PubMed ID: 27234973
[TBL] [Abstract][Full Text] [Related]
17. Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker
Van Cutsem E; Paccard C; Chiron M; Tabernero J
Clin Cancer Res; 2020 Feb; 26(3):717-725. PubMed ID: 31727675
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
[TBL] [Abstract][Full Text] [Related]
19. Ziv-aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer.
Perkins SL; Cole SW
Ann Pharmacother; 2014 Jan; 48(1):93-8. PubMed ID: 24259608
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
